|
SGX Pharmaceuticals, Inc. |
|
|
10505 Roselie Street
San Diego, CA 92121 USA
phone:858.558.4850
fax:858.558.4859
|
|
| Symbol |
SGXP |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.stromix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Discover and development of cancer therapeutics. |
|
| Management |
| Michael Grey, President and Chief Executive Officer; Stephen K. Burley, M.D., Chief Scientific Officer and Senior Vice President, Research; W. Todd Myers, Chief Financial Officer; Annette North, Esq., Vice President, Legal Affairs and Corporate Secretary; Siegfried Reich, Ph.D., Vice President, Drug Discovery; Sean A. McCarthy, D. Phil., Vice President, Business Development |
| |
|
|
|
|
|
|
|
| Keywords |
| cancer therapeutics, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, tumor |
|
|
|
| Description |
|
SGX Pharmaceuticals (formerly Structural GenomiX) is focused on the discovery, development and commercialization of innovative cancer therapeutics. |
|
| Products / Services |
The Company is developing Troxatyl, a novel compound that is currently in a pivotal Phase II/III clinical trial for the third-line treatment of Acute Myelogenous Leukemia (AML). They also plan to develop Troxatyl in combination with Ara-C for the second-line treatment of AML, and develop Troxatyl for the treatment of Myelodysplastic Syndromes (MDS) and for various solid tumors.
|
|
|
| Strategy |
In addition, SGX is building an internal oncology product pipeline and generating lead compounds for multiple partners through the application of their proprietary fragment-based drug discovery platform, Fragments of Active Structures (FAST).
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
